KRT7 and lung cancer: Even in entities not listed as distinct favorable subtypes in the ESMO classification, as is the case for CK7+ TTF1+ carcinomas in patients with mediastinal or hilar lymph nodes or pleural carcinosis, the treatment should be dictated by the most likely primary, in this case lung cancer.